Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

College Point, New York Clinical Trials

A listing of College Point, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (28) clinical trials

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

This is a randomized, multicenter, double-blind, parallel-group, active-control study. Approximately 280 patients aged 18 years will be enrolled in the study globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan. The purpose of the study is to evaluate ...

Phase

2.5 miles

Learn More »

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC HCC and HNSCC

The primary objective of the study is to evaluate the clinical activity of neoadjuvant cemiplimab therapy in patients with resectable Non-small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC), and Head and neck squamous cell carcinoma (HNSCC) lesions, as measured by pathological evaluations of resected tumors. The secondary objectives of the ...

Phase

5.24 miles

Learn More »

Evaluating the Safety Tolerability Pharmacokinetics and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121 PGDM1400 10-1074 and VRC07-523LS Administered Via Intravenous Infusion in Healthy HIV-uninfected Adult Participants

This study will evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adults. Participants will initially be enrolled into one of three groups. At Day 0, Groups 1, 2, and 3 will receive dual ...

Phase

6.03 miles

Learn More »

Assessment of the Safety Tolerability and Effectiveness of Rifapentine Given Daily for LTBI

This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care, control arm) of latent M. tuberculosis infection (LTBI). This trial is conducted among persons who ...

Phase

6.03 miles

Learn More »

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.

Phase

6.07 miles

Learn More »

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.

Phase

6.07 miles

Learn More »

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

The specific objectives of this study are to: Determine whether rituximab/belimumab/mmf is safe and tolerable in the treatment of patients with early diffuse cutaneous (dc)SSc when compared to patients treated with placebo/placebo/mmf, as assessed by comparison of adverse and serious adverse effects. In this study stand of care will be ...

Phase

6.07 miles

Learn More »

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS)who have completed the ORARIALS-01 trial.

Phase

6.07 miles

Learn More »

Using ICG Dye to Identify Ovarian Lymph Nodes in Women Undergoing Risk-Reducing Minimally Invasive Surgery

The purpose of this study is to explore whether or not it is possible to identify the ovarian sentinel lymph node using indocyanine green / ICG dye in women undergoing minimally invasive surgery for an adnexal mass.

Phase N/A

6.07 miles

Learn More »

A Trial Investigating the Safety Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

During the first four weeks of the trial, participants will be randomly assigned to one of four groups: three groups will receive fixed doses of TransCon PTH and one group will receive placebo. TransCon PTH or placebo will be administered as a subcutaneous injection using a pre-filled injection pen. Neither ...

Phase

6.17 miles

Learn More »